Advantages of Biocytogen's Novel Hu-VHH Platform
- The Single VHH (variable heavy domain of heavy chain) is only half the size of scFv (single-chain fragment variable) proteins, enabling better penetration of solid tumors and the blood-brain barrier.
- Based on RenNano, fully human heavy-chain antibodies (HCAbs) or fully human VHH (Hu-VHH) do not require humanization in vitro, resulting in a faster and more cost-effective antibody discovery process.
- It can produce fully human HCAbs with sequence diversity, good affinity, and favorable pharmacokinetic properties.
- Compared with scFv-based formats, the compact architecture of Hu-VHH enables greater design flexibility and simplified molecular engineering, which is particularly advantageous for complex modalities such as bispecific/multispecific antibodies and cell therapies.
Biocytogen's RenNano-based Hu-VHH Platform
Using
RenNano, Biocytogen is creating a Hu-VHH antibody library for high-potential therapeutic targets including tumor-associated antigens, GPCRs, immune checkpoints, cytokine/chemokines, and factors related to neurological diseases.
Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale Hu-VHH development abilities with collaborators’ expertise in Hu-VHH-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs, and RACs, to develop novel drugs with first-in-class and/or best-in-class potentials.
Off-the-shelf Hu-VHHs Available for Partnership
| Therapeutic Area |
Target(s) |
Immunization |
- Development
-
Hits
selection
Leads
selection
Candidate
selection
|
Preclinical |
IND |
| Oncology |
VEGFA |
|
| 4-1BB |
|
| CD98 |
|
| ILЗRA |
|
| MUC16 |
|
| 0X40 |
|
| ADAM9 |
|
| CD28 |
|
| CD38 |
|
| CD3e |
|
| CD71 |
|
| DLL3 |
|
| EPHA2 |
|
| FAP |
|
| GPRC5D |
|
| GUCY2C |
|
| HER3 |
|
| IL6R |
|
| MSLN |
|
| Nectin-4 |
|
| PD-L1 |
|
| PSMA |
|
| PTK7 |
|
| ROR1 |
|
| TROP2 |
|
| Infectious Diseases |
RSV |
|
| Metabolism |
CD38 |
|
